January 2019 Newly Funded Projects
The table below covers newly awarded grants from our January 2019 grant cycle, totaling nearly $4.15M, that are funded in partnership with EB Research Foundation of Australia, EB Medical Research Foundation, and Cure EB.
INSTITUTION |
PROJECT NAME |
PRINCIPAL INVESTIGATOR(S) |
AMOUNT AWARDED |
PolarityTE |
Genetic modification of a commercially available Autologous Homologous Skin Construct for permanent epidermal replacement in Recessive Dystrophic Epidermolysis Bullosa |
Nikolai Sopko MD PhD |
$300,000 |
Columbia University |
Development of a drug testing platform for recessive dystrophic epidermolysis bullosa squamous cell carcinoma using induced pluripotent cancer cells |
Joanna Jackow PhD |
$551,250 |
Neem Biotech Limited |
Identification of ajoene analogues for the treatment of epidermolysis bullosa |
Tracy Nevitt PhD |
$112,400 |
Thomas Jefferson University |
Targeting fibrosis for RDEB therapy in preclinical animal models |
Andrew South PhD |
$159,054 |
University of Colorado |
A Comprehensive Stem Cell Biobank for EB Patients |
Ganna Bilousova PhD Anna L. Bruckner MD Dennis R Roop PhD Igor Kogut PhD |
$286,815 |
University of Minnesota |
Next Generation Genome Editing for RDEB |
Jakub Tolar MD PhD |
$1,000,000 |
University of Colorado |
A cGMP-Compliant Library Master Cell Bank as a Necessary Prerequisite for an iPSC-Based Clinical Trial for EB |
Igor Kogut PhD Ganna Bilousova PhD Dennis R Roop PhD |
$964,176 |
University of Colorado |
Developing an iPS Cell-based Therapy for Epidermolysis Bullosa Simplex |
Dennis R Roop PhD Ganna Bilousova PhD Igor Kogut PhD Anna Bruckner MD |
$518,638 |
Université du Québec à Chicoutimi |
Inactivation of epidermolysis bullosa simplex dominant mutations by allele-specific CRISPR/Cas9 |
Catherine Laprise PhD Lucie Germain PhD Jacques-P Tremblay PhD |
$255,400 |
Wings Therapeutics |
Clinical Development of QR-313 for Treatment of RDEB |
Deborah Ramsdell |
$1,500,000 |